The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis.

Vandenplas, Yannick; Simoens, Steven; Van Wilder, Philippe; Vulto, Arnold G; Huys, Isabelle

Vandenplas, Yannick; Simoens, Steven; Van Wilder, Philippe; Vulto, Arnold G; Huys, Isabelle.

Afiliação

Vandenplas Y; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. yannick.vandenplas@kuleuven.be.
Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Van Wilder P; Ecole de Santé Publique, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Vulto AG; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Huys I; Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.

Health Res Policy Syst ; 21(1): 68, 2023 Jul 06.

Article em En | MEDLINE | ID: mdl-37415219

Assuntos

Medicamentos Biossimilares; Humanos; Bélgica; Medicamentos Biossimilares/uso terapêutico; Etanercepte/uso terapêutico; Filgrastim/uso terapêutico; Análise de Séries Temporais Interrompida

Palavras-chave

ARIMA; Belgium; Biological; Biosimilar; Interrupted time series; Policy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Health Res Policy Syst Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google